Since they were founded, KYMOS and PHARMAPROGRESS have been devoted to providing analytical services for pharmaceutical companies. The knowledge of the physicochemical properties of drugs and how they interact with the organism is essential to understanding the processes of absorption, distribution, metabolism, excretion and toxicity. So, analysis is an essential part of all phases of research, development and marketing for pharmaceutical products. We focus on providing analytical support services in two different domains: bioanalysis and medicinal chemistry. Both activities play an important role in development.

A good bioanalytical method that has been properly validated for each species and biological matrix is required to correlate the toxicity of the drug during preclinical toxicokinetics and to characterize the pharmacokinetics and pharmacodynamics of the drug in the preclinical phase. Later on, during the clinical phase, other studies require bioanalyses: dose searching, pK/pD, bioequivalence, toxicity, interaction, efficacy.

Medicinal chemistry is another activity that has to be started very early on in the development of a new drug. Standardization of the drug product is always one of the first things to do. When the synthetic route is established, the profile of impurities gains importance, so it may have an impact on toxicity. Stability properties must be known in advance to prevent problems during development. Validation of the tests is not always required and the extent of analytical testing necessary depends on the stage of development. In short, we have the experience to advise you at any step and provide you with first-class analytical and scientific support.


Chemistry, manufacturing and control analytical services are conducted under GMP compliance. During development, some phases may be executed according to GLP at the Client's request.



Releasing a biosimilar product to market is extremely challenging. On the one hand, only a very well-equipped laboratory has the cappabilities to conduct this activity, ensuring purity, identity, and potency. On the other hand, the testing site should be GMP certified and have manufacturing authorization, subject to periodic inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Working with biologic drugs involves a huge analytical effort to understand the characteristics of the whole molecule in depth. Various methods and technologies are requires to get the analytical fingerprint of the molecule. An extensive analytical characterization based on an orthogonal approach is a key element for the project's success. We offer complex characterization projects for innovative biologics and comparison of biosimilars.

Devices used for inhaled and nasal drug delivery are collectively referred to as Orally Inhaled and Nasal Drug Products (OINDPs). The range of products available is broad, encompassing inhalers (metered dose, dry powder and aqueous droplet), nebulizers (jet, ultrasonic and vibrating mesh) and nasal (aqueous based, dry powder and propellant based). Two of the main factors largely recognized as Critical Quality Attributes in the testing of OINDPs are the delivered dose and particle size distribution.

In recent years, the pharmaceutical industry has developed a better understanding of the impact of extractables and leachables on patient safety and drug product interaction, leading to increased scrutiny from regulators. A study should be conducted to determine the profile of extractables in the container closure components that are in contact with the formulation during storage and/or use.

We have extensive experience performing analytical tests for APIsexcipientsintermediate productsfinished productspackaging materials and process environment samples. The most suitable method is used, according to customer specifications or the relevant Pharmacopoeias description (EP, USP, BP, JP). If non-compendial methods need to be used, we develop and validate the method from scratch or transfer the method from the manufacturer.

We have a comprehensive knowledge in the development and validation of analytical proprietary and non-proprietary methods for excipients, APIs, intermediate products and finished products, according to the ICH Q2 (R1) in line with Q6A and Q6B. Our methods are ready for transfer to contract-giver, in compliance with EU-GMP chapter 6, performing a comparative test, a co-validation in two sites or a revalidation.

We provide full CH studies and on-going stability programmes for third parties. These services, at the client's request, can include: method transfer, method improvement, analytical standards management, storage at different conditions, scheduling of analytical timepoints, full analysis and out-of-trend (OOT) and out-of-specification (OOS) management. These tasks are always conducted according to procedures agreed upon with the client.

We provide microbiological testing for sterile and non-sterile APIs and drug products. Our fully-equipped laboratory includes a cleanroom with airlock technology and HEPA filters for the most sensitive operations. Our 4-glove isolator ISOFLEX-S is equipped with a Steritest pump and an H2O2 generator. The main advantage of using isolation technology for sterility testing is to ensure that no fals- positive results are obtained.

Both laboratories, KYMOS and PHARMAPROGRESS are GMP certified and we have a partial manufacturer authorization for Quality Control purposes. We offer the following services:

  • APIs Certificate of Analysis according to the relevant Pharmacopoeias
  • Individual parameter determination to be included in your batch Certificate of Analysis
  • Full analysis of all parameters to issue a stand alone batch Certificate of Analysis
  • Batch Testing and Batch Release of clinical batches
  • Batch Testing and Batch Release of marketing batches
  • Importation into the EU of medicinal drug products (human, veterinary or investigational)

We provide Elemental Impurities testing using ICP-MS according to ICH Q3D and European Pharmacopoeia and USP General Chapters <232>, <233> and <2232> for drug substances, excipients and drug products, including the 24 elements listed in the ICH Q3D guideline and/or others.

We can support you in conducting potency assays of vaccines for quality control in order to substitute "in vivo" testing. We can develop and validate a new method from scratch or improve on pre-existing methods or commercial kits. We can transfer these methods to your lab or keep it in house to provide you routine quality control of batches under GMP.

Revised monographs in the European Pharmacopoeia on heparin sodium (0333) and heparin calcium (0332) are in force from January 1st, 2015. These monographs include chromogenic anti-factor IIa and anti-factor Xa assays. The USP monograph for heparin sodium had been updated previously.

We have implemented and validated these challenging assays according to the USP monograph and they are ready to be used for drug products and drug substances. However, personalized method adjustments are necessary on a case-by-case basis.

Cleaning validation is a significant GMP activity to prevent contamination of biopharmaceutical products by ensuring that the processing equipment is suitable for later manufacturing processes. Potential contaminants include residues of the active pharmaceutical ingredients or their related substances, and residues from the products used during the cleaning process such as solvents or detergents. This is particularly important for highly-sensitizing compounds such as antibiotics, hormones and cytotoxics and in the case of parenteral drug products.


Chemistry, manufacturing and control analytical services are conducted under GMP compliance. During development, some phases may be executed according to GLP at the Client's request.



We can develop and validate bioanalytical methods for innovative small molecules using mass spectrometry. We have the experience that comes from being the partner selected by several companies to develop of proprietary methods from project kick-off to market.

  • Research: in vitro and in vivo ADMET studies  
  • Early development: preliminary pharmacokinetics
  • Regulatory preclinical in different species: toxicokinetics, pharmacokinetics, pharmacodynamics
  • Phase I studies: pharmacokinetics, dose searching studies, single and repeated dose
  • Phase II to IV clinical studies: related biomarkers, interaction with concomitant medication and feed

We have a great capacity for processing samples, up to 10.000 per month.

We are experts in bioanalysis for bioequivalence studies in collaboration with the sponsor and/or the selected clinical phase centre. We have a long list of validated bioanalytical methods and when not available, we perform the method validation free of charge for our clients in a very short period of time. LIST OF VALIDATED METHODS.

Moreover, we are also a well-reputed service provider for comprehensive management of bioequivalence studies thanks to strategic alliances with reliable GCP-compliant clinical phase centres.

We provide services of pharmacokinetics calculations and statistics for bioanalytical data coming from preclinical and clinical studies.

  • Non-Compartmental Analysis (NCA)
  • Compartmental modelling using built-in models or self-generated ones
  • Bioequivalence (AUC, Tmax, Cmax)

We use the Phoenix WinNonlin® software that has been properly validated according to guidelines for IT system validation.

We offer you our experience in studies on Percutaneous Absorption for topical semisolid drug products using vertical diffusion cells (or Franz cells) according to the EMA Draft Guideline on Quality and equivalence of topical products. Both In Vitro Release Test and In Vitro Permeation Test are available using the Hanson difussion Phoenix instrument.